Skip to content

Assessment of a pharmacokinetic and pharmacodynamics interaction between simvastatin and Ginkgo biloba extracts in health subjects

Assessment of a pharmacokinetic and pharmacodynamics interaction between simvastatin and Ginkgo biloba extracts in health subjects

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TTRCC-12002801
Enrollment
Unknown
Registered
2012-12-22
Start date
2010-04-15
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

Interventions

group 1:administrated with simvastatin and Ginkgo biloba extract
group 2:administrated with simvastatin

Sponsors

Institute of Clinical Pharmacology, Central South University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
19 Years to 25 Years

Inclusion criteria

Inclusion criteria: Male, 19-25 years of age (including boundary value); subjects body mass index (BMI): 19-25 Male, 19-25 years of age (including boundary value); subjects body mass index (BMI): 19-25 (including boundary value); According to the medical examination, vital signs, electrocardiogram and clinical laboratory result, participants are healthy, and the inspection was taken 1 week before the drug administration; subjects are able to read and understand the contents of the informed consent, and sign the informed consent before any research related operations; subjects are not taken any other drugs two weeks before the test.

Exclusion criteria

Exclusion criteria: Subjects with arrhythmia, bronchial or cardiovascular disease history, diabetes, thyrotoxicosis, Parkinson's syndrome, or any other disease or physiology that can interference test results; with disease that can affect drug absorption or metabolic disease of the gastrointestinal tract; have drug abuse history or positive urine drug test results in the past five years; used other medicines within 14 days before the test; participated in other drug experiments within 30 days before the test; Serious blood loss or donation (500 ml) within 30 days before the test.

Design outcomes

Primary

MeasureTime frame
blood drug concentration;

Countries

China

Contacts

Public ContactHong-Hao Zhou, Lan Fan
fanlan_038038@163.com+86 0731 84805380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026